2 Top Healthcare Stocks That Could Be Bought Out in 2022

·6-min read
2 Top Healthcare Stocks That Could Be Bought Out in 2022

The healthcare sector has been a serious disappointment for investors in 2021. After a banner year in 2020 thanks to the advent of several highly lucrative COVID-19 vaccines and therapies, the closely watched SPDR S&P Biotech ETF (NYSEMKT: XBI) has now fallen by a staggering 11.5% so far this year. A healthy cadre of headline-grabbing new technologies from biotech pioneers such as Allogene Therapeutics, Bluebird Bio, CRISPR Therapeutics (NASDAQ: CRSP), Sarepta Therapeutics, among many others, have failed to live up to expectations and/or exhibited worrying safety signals.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting